MedPath

Investigation of SGLT2 inhibitors for normal glucose tolerance

Not Applicable
Conditions
normal glucose tolerance
Registration Number
JPRN-UMIN000013747
Lead Sponsor
Dianetes and Endocrinolohgy
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
5
Inclusion Criteria

Not provided

Exclusion Criteria

1) Type 1 DM (including SPIDDM) 2) Allergy for SGLT2 or Ipragliflozin 3) severe liver dysfunction 4) severe renal dysfunction 5) severe cardiac dysfunction 6) less than 20 years or over 61 years 7) pregnancy or breast feeding 8) mental retardation or dementia 9) systematic steroid administered 10) other inappropriate persons judged by investigators

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
parameter of insulin secretion(Insulinogenic index, HOMA-beta, AUC-IRI) parameter ofinsulin sensitivity (HOMA-R, Composite indexGIR)
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath